RSS

TxCell

A biotechnology company, TxCell, Inserm Transfert and Nantes University have signed a R&D collaboration agreement for the development of chimeric antigen receptor (CAR) engineered CD8+Treg cells (CAR-Tregs). more

News

TxCell, a biotechnology company developing personalised cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, will participate at the second French Life Sciences Days. more

News